Acrivon Therapeutics Conference Call Summary Company Overview - **Company**: Acrivon Therapeutics (NasdaqGM:ACRV) - **Focus**: Development of ACR-368 for endometrial cancer treatment Key Industry Insights - **Industry**: Oncology, specifically gynecological cancers - **Current Study**: ACR-368 registrational intent Phase 2B study in subjects with endometrial cancer Core Points and Arguments 1. **Unmet Need in Endometrial Cancer**: - Serous endometrial cancer is aggressive, accounting for over 50% of mortality with a median overall survival of only about 3 years [5][16] - Limited treatment options exist, highlighting the need for new therapies [5][16] 2. **ACR-368 Overview**: - ACR-368 is a selective CHK1/2 inhibitor, with a proprietary biomarker test (OncoSignature) predicting its efficacy [9][10] - The trial enrolled patients who had relapsed after prior platinum-based chemotherapy and checkpoint therapy [10] 3. **Clinical Trial Results**: - Overall response rate (ORR) in biomarker-positive patients was 39%, with a disease control rate of 81% [12] - In patients with 2 or fewer prior therapies, ORR was 44% for biomarker-positive and 26% for biomarker-negative groups [12] - For serous cancers, the response rate reached 52% with a disease control rate of 74% [13] 4. **Safety Profile**: - ACR-368 demonstrated a favorable safety profile with manageable hematological adverse events and minimal gastrointestinal toxicities [13][14] - The absence of serious adverse events compared to other therapies was noted [14] 5. **Future Studies**: - Expansion of the study to include a biopsy-independent cohort for serous histology patients is planned [14][17] - The study aims to treat up to 90 patients across over 20 sites in Europe [14] 6. **Market Opportunity**: - Serous endometrial cancers represent about 10% of cases but account for over 50% of deaths, indicating a significant market need [16][34] - Estimated 60,000-70,000 patients in the U.S. may benefit from ACR-368 in the recurrent setting [34] 7. **Comparative Efficacy**: - ACR-368's efficacy significantly exceeds current standard treatments, which have response rates around 15% [19][26] - The potential for ACR-368 to be used in second-line and third-line settings for serous endometrial cancer is emphasized [26][27] 8. **Global Expansion**: - The trial's design allows for easier patient recruitment in Europe due to the elimination of biopsy requirements [32][100] - This could expedite the approval process and enhance patient access to the treatment [32][100] Additional Important Insights - **Biomarker Relevance**: The OncoSignature test showed higher biomarker levels in serous patients, indicating a strong biological rationale for ACR-368's efficacy in this subgroup [98] - **Regulatory Considerations**: The discussion highlighted the complexities of FDA approval processes, emphasizing the need for robust data on efficacy and safety [106][110] - **Panel Consensus**: Experts expressed strong support for incorporating ACR-368 into treatment algorithms for recurrent serous endometrial cancer due to its promising results and manageable toxicity [28][29][30]